Amrit Ray
Director/Board Member chez ULTRAGENYX PHARMACEUTICAL INC.
Fortune : 573 353 $ au 31/03/2024
Profil
Amrit Ray is an Independent Director at Ultragenyx Pharmaceutical, Inc., a Director at Everylife Foundation for Rare Diseases, a Director at CorEvitas LLC, and an Independent Director at Fortrea Holdings, Inc. He was previously the Chief Medical Officer at Johnson & Johnson, the Global President-Research & Development at Pfizer Inc., and the Chief Patient Officer at Biohaven Pharmaceuticals, Inc. Dr. Ray received his undergraduate and doctorate degrees from The University of Edinburgh and his MBA from Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/06/2023 | 12 280 ( 0,01% ) | 573 353 $ | 31/03/2024 |
Postes actifs de Amrit Ray
| Sociétés | Poste | Début |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Director/Board Member | 19/04/2022 |
| FORTREA HOLDINGS INC. | Director/Board Member | 29/06/2023 |
CorEvitas LLC
 CorEvitas LLC BiotechnologyHealth Technology CorEvitas LLC engages in the provision of medical research services. It offers real-world evidence solutions; safety; patient engagement; precision medicine biorepository. The company was founded by Joel Kremer in 2001 and is headquartered in Waltham, MA. | Director/Board Member | 03/08/2021 |
Everylife Foundation for Rare Diseases
 Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services EveryLife Foundation for Rare Diseases is a non-profit organization that aims to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The non-profit company is based in Novato, CA and was founded by Emil D. Kakkis. The foundation provides training, education, resources, and opportunities to make patient voices heard, with the belief that activating the patient advocate can change public policy and save lives. | Director/Board Member | - |
Anciens postes connus de Amrit Ray
| Sociétés | Poste | Fin |
|---|---|---|
Biohaven Pharmaceuticals, Inc.
 Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01/12/2022 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| JOHNSON & JOHNSON | Chief Tech/Sci/R&D Officer | - |
Formation de Amrit Ray
| The University of Edinburgh | Doctorate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| PFIZER, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| FORTREA HOLDINGS INC. | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Everylife Foundation for Rare Diseases
Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services EveryLife Foundation for Rare Diseases is a non-profit organization that aims to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The non-profit company is based in Novato, CA and was founded by Emil D. Kakkis. The foundation provides training, education, resources, and opportunities to make patient voices heard, with the belief that activating the patient advocate can change public policy and save lives. | Commercial Services |
CorEvitas LLC
CorEvitas LLC BiotechnologyHealth Technology CorEvitas LLC engages in the provision of medical research services. It offers real-world evidence solutions; safety; patient engagement; precision medicine biorepository. The company was founded by Joel Kremer in 2001 and is headquartered in Waltham, MA. | Health Technology |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
